Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

3.88
Delayed Data
As of 11:44am ET
 -0.01 / -0.26%
Today’s Change
1.83
Today|||52-Week Range
13.90
+100.00%
Year-to-Date
Pernix: An Investor's Rationale to Staying Long
Mar 23 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close3.89
Today’s open3.82
Day’s range3.82 - 3.93
Volume40,031
Average volume (3 months)622,720
Market cap$37.0M
Dividend yield--
Data as of 11:44am ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)-198.92%
Earnings growth (this year)+41.73%
Earnings growth (next 5 years)+13.60%
Revenue growth (last year)+44.44%
P/E ratioNM
Price/Sales0.89
Price/Book0.72

Competitors

 Today’s
change
Today’s
% change
THLDThreshold Pharmaceut...+0.05+10.09%
CHMAChiasma Inc+0.05+3.12%
PRPHProPhase Labs Inc-0.00-0.09%
TPIVTapImmune Inc+0.03+0.63%
Data as of 12:03pm ET, 03/24/2017

Financials

Next reporting dateMarch 29, 2017
EPS forecast (this quarter)-$3.15
Annual revenue (last year)$175.9M
Annual profit (last year)-$148.3M
Net profit margin-84.34%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
John A. Sedor
President, Chief Financial Officer &
Director
Graham G. Miao
Corporate headquarters
Morristown, New Jersey

Forecasts


Search for Jobs